Astrazeneca (AZN) to Release Quarterly Earnings on Wednesday

Astrazeneca (NYSE:AZN) is expected to be releasing its Q1 2026 results before the market opens on Wednesday, April 29th. Analysts expect Astrazeneca to post earnings of $2.53 per share and revenue of $14.7421 billion for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, April 29, 2026 at 6:00 AM ET.

Astrazeneca Stock Down 2.4%

AZN opened at $195.94 on Wednesday. The firm has a market cap of $303.88 billion, a price-to-earnings ratio of 33.75, a price-to-earnings-growth ratio of 1.51 and a beta of 0.35. Astrazeneca has a 52 week low of $132.32 and a 52 week high of $212.71. The company has a debt-to-equity ratio of 0.51, a current ratio of 0.94 and a quick ratio of 0.72.

Astrazeneca Dividend Announcement

The business also recently declared a dividend, which was paid on Monday, March 23rd. Stockholders of record on Friday, February 20th were given a $1.595 dividend. This represents a dividend yield of 156.0%. The ex-dividend date was Friday, February 20th. Astrazeneca’s dividend payout ratio (DPR) is currently 74.83%.

Hedge Funds Weigh In On Astrazeneca

A number of large investors have recently modified their holdings of AZN. Triumph Capital Management acquired a new position in shares of Astrazeneca during the 3rd quarter worth about $25,000. JPL Wealth Management LLC acquired a new position in shares of Astrazeneca during the 3rd quarter worth about $35,000. Johnson Financial Group Inc. boosted its stake in shares of Astrazeneca by 1,265.0% during the 3rd quarter. Johnson Financial Group Inc. now owns 546 shares of the company’s stock worth $42,000 after buying an additional 506 shares during the last quarter. Acumen Wealth Advisors LLC acquired a new position in shares of Astrazeneca during the 4th quarter worth about $47,000. Finally, Binnacle Investments Inc boosted its stake in shares of Astrazeneca by 21.8% during the 3rd quarter. Binnacle Investments Inc now owns 660 shares of the company’s stock worth $51,000 after buying an additional 118 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Astrazeneca

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: Ultomiris met the primary endpoint in a Phase III trial for IgA nephropathy (statistically significant reduction in proteinuria), supporting prospects for accelerated approvals and label expansion in a rare kidney disease. AstraZeneca’s Ultomiris reduces urine protein in late-stage trial of rare kidney disease
• Positive Sentiment: Tozorakimab delivered a third Phase III success (MIRANDA) with a sharp reduction in moderate‑to‑severe COPD flare‑ups; Citi sees blockbuster potential (~$5bn peak sales) — a material long‑term revenue catalyst if launches and uptake follow. AstraZeneca’s tozorakimab delivers sharp reduction in COPD flare‑ups
• Neutral Sentiment: Broker consensus remains constructive (average “Moderate Buy”), which supports near‑term analyst backing but may already be reflected in the share price. Astrazeneca Plc (NYSE:AZN) Given Average Rating of “Moderate Buy” by Brokerages
• Negative Sentiment: AstraZeneca’s CEO warned Germany risks missing out on new drugs if it tightens pharmaceutical spending — a signal of potential pricing/reimbursement headwinds in a major European market that could slow adoption and revenue ramp for new launches. Germany risks missing out on new drugs, AstraZeneca CEO tells paper

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on AZN shares. TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Wall Street Zen lowered Astrazeneca from a “buy” rating to a “hold” rating in a research report on Saturday, April 4th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research note on Friday, February 6th. Weiss Ratings assumed coverage on shares of Astrazeneca in a report on Wednesday, March 11th. They set a “buy (b)” rating for the company. Finally, Citigroup started coverage on shares of Astrazeneca in a report on Tuesday, January 27th. They issued a “buy” rating on the stock. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Astrazeneca currently has a consensus rating of “Moderate Buy” and a consensus target price of $102.67.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.